Elevated endotoxin levels in human intravenous immunoglobulin concentrates caused by (1→3)-β-D-glucans

PDA Journal of Pharmaceutical Science and Technology

Volumn 64, Issue 6, 2010, Pages 536-544

  Buchacher, Andrea ^a   Krause, Dagmar ^a   Wiry, Gerda ^a   Weinberger, Josef ^a  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

Author keywords

(1 3) D glucan; Endotoxin; IVIG; Limulus amoebocyte lysate (LAL); LPS

Indexed keywords

1,3 BETA GLUCANASE; CELLULOSE; ENDOTOXIN; IMMUNOGLOBULIN; PYROGEN; BETA GLUCAN; GLUCAN; HUMAN GROWTH HORMONE;

ARTICLE; DRUG SYNTHESIS; HUMAN; LIMULUS LYSATE TEST; NONHUMAN; RABBIT; TEMPERATURE; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRAVENOUS DRUG ADMINISTRATION;

ANIMALS; BETA-GLUCANS; CELLULOSE; ENDOTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCANS; HUMAN GROWTH HORMONE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; LIMULUS TEST;

EID: 80053547373     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cooper, J. F.; Weary, M. E.; Jordan F. T. The impact of non-endotoxin LAL-reactive materials on Limulus amebocyte lysate analyses. PDA J. Pharm. Sci. Technol. 1997, 51 (1), 2-6. (Pubitemid 27443529)
2. Ikemura, K.; Ikegami, K.; Shimazu, T.; Yoshioka, T.; Sugimoto, T. False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J. Clin. Microbiol. 1989, 27 (9), 1965-1968. (Pubitemid 19208975)
3. Usami, M.; Ohata, A.; Horiuchi, T.; Nagasawa, K.; Wakabayashi, T.; Tanaka, S. Positive (1→3)-β-D-glucans in blood components and release of (1→3)-β-D-glucans from depth-type membrane filters for blood processing. Transfusion 2002, 42 (9), 1189-1195.
4. Bonomini, V.; Coli, L.; Felicianngeli, G.; Nanni Costa, A.; Scolari, M. P. Long-term evaluation of synthetic and cellulosic membranes in dialysis. Int. J. Artif. Organs 1994, 17 (7), 392-398. (Pubitemid 24300554)
5. Human normal immunoglobulin for intravenous administration. In European Pharmacopoeia 6.6, Council of Europe, Strasbourg Cedex, France, p 5268.
6. Cohn, E. J.; Strong, L. E.; Hughes, W. L.; Mulford, D. J.; Ashworth, J. N.; Melin, M.; Taylor, H. L. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 1946, 68 (3), 459-475.
7. Endotoxins: Pyrogens, LAL Testing and Depyrogenation, 3rd ed.; Williams, K. L., Ed.; CRC Press, New York, 2007; p 191.
8. Bacterial endotoxins. In European Pharmacopoeia 6.0, monograph 2.6.14, Council of Europe: Strasbourg Cedex, France, p 46.
9. Bacterial endotoxin test. In Pharmacopeia of the United States of America, monograph -85-, Rockville, MD.
10. Loverock, B.; Simon, B.; Burgenson, A.; Baines, A. A recombinant factor C procedure for the detection of gram-negative bacterial endotoxin. Pharmacopeial Forum 2009, 35 (6), 1613-1621.
11. Pyrogens. In European Pharmacopoeia 6.0, monograph 2.6.8, Council of Europe, Strasbourg Cedex, France, p 164.
12. Twohy, C. W.; Nierman, M. L.; Duran, A. P.; Munson, T. E. Comparison of limulus amebocyte lysates from different manufacturers. J. Parenter. Sci. Technol. 1983, 37 (3), 93-96.
13. McCullough, K. Z. Variability in the LAL test. J. Parenter. Sci. Technol. 1990, 44 (1),19-21. (Pubitemid 20141464)
14. Henne, W.; Schulze, H.; Pelger, M.; Tretzel, J.; von Sengbusch, G. Hollow-fiber dialyzers and their pyrogenicity testing by Limulus amebocyte lysate. Artif. Organs 1984, 8 (3), 299-305.
15. Munson, T. Statement concerning Glucans and LAL-Reactive Material in Pharmaceutical and Medical Devices. Federal Drug Administration memorandum, 1992.
16. Bergamo Collaborative Dialysis Study Group. Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophan. Kidney Int. 1991, 40 (4), 714-719.
17. Mujais, S. K.; Ivanovich, P.; Bereza, L. A.; Vidovich, M. In Dialysis Membranes: Structure and Predictions, 113; Bonomini, V. Berland, Y. Ronco, C., Eds.; Karger: Basel, 1995; p 101.
18. Yoshida, M.; Roth, R. I.; Grunfeld, C.; Feingold, K. R.; Levin, J. Soluble (1→3)-β-D-glucan purified from Candida albicans: biologic effects and distribution in blood and organs in rabbits. J. Lab. Clin. Med. 1996, 128 (1), 103-114. (Pubitemid 26369176)
19. Kato, A.; Takita, T.; Furuhashi, M.; Takahashi, T.; Maruyama, Y.; Hishida, A. Elevation of blood (1→3)-β-D-glucan concentrations in hemodialysis patients. Nephron 2001, 89 (1), 15-19. (Pubitemid 32799827)
20. Mennink-Kersten, M. A.; Warris, A.; Verweij, P. E. 1,3-β-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N. Engl. J. Med. 2006, 354 (26), 2834-2835. (Pubitemid 43974215)
21. Ascioglu, S.; Rex, J. H.; de Pauw, B.; Bennett, J. E.; Bille, J.; Crokaert, F.; Denning, D. W.; Donnelly, J. P.; Edwards, J. E.; Erjavec, Z.; Fiere, D.; Lortholary, O.; Maertens, J.; Meis, J. F.; Patterson, T. F.; Ritter, J.; Selleslag, D.; Shah, P. M.; Stevens, D. A.; Walsh, T. J. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 2002, 34 (1), 7-14. (Pubitemid 33152659)
22. Obayashi, T.; Yoshida, M.; Mori, T.; Goto, H.; Yasuoka, A.; Iwasaki, H.; Teshima, H.; Kohno, S.; Horiuchi, A.; Ito, A., et al. Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995, 345 (8941), 17-20.
23. Ostrosky-Zeichner, L.; Alexander, B. D.; Kett, D. H.; Vazquez, J.; Pappas, P. G.; Saeki, F.; Ketchum, P. A.; Wingard, J.; Schiff, R.; Tamura, H.; Finkelman, M. A.; Rex, J. H. Multicenter clinical evaluation of the (1→3)-β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 2005, 41 (5), 654-659. (Pubitemid 41170353)
24. Odabasi, Z.; Mattiuzzi, G.; Estey, E.; Kantarjian, H.; Saeki, F.; Ridge, R. J.; Ketchum, P. A.; Finkelman, M. A.; Rex, J. H.; Ostrosky-Zeichner, L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 2004, 39 (2), 199-205. (Pubitemid 38971490)